Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 6/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | GBA1 | P04062 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1922252 | 0.88 | MEN1 (0.46) | SCDKMT2AMEN1ATMSLC6A9 | |
| SCHEMBL3826357 | 0.82 | SCD (0.61) | SCDLMNAKDM4ESMN1; SMN2HTT | |
| SCHEMBL1094784 | 0.82 | SCD (0.61) | SCDLMNAKDM4ESMN1; SMN2HTT | |
| SCHEMBL3677226 | 0.81 | SCD (0.71) | SCDKMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL14143707 | 0.81 | SCD (0.62) | SCDLMNAALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL14143697 | 0.81 | SCD (0.64) | SCDLMNAKDM4ESMN1; SMN2HTT | |
| SCHEMBL3825613 | 0.81 | SCD (0.59) | SCDLMNAKDM4ESMN1; SMN2HTT | |
| SCHEMBL14143564 | 0.81 | KDM4E (0.64) | SCDKMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL3411182 | 0.79 | ALDH1A1 (0.67) | SCDKMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL27636544 | 0.79 | MAPT (0.62) | KMT2AMEN1ATMMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651606-B1 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2012-10-24 | — | — | EP | disclosed |
| US-8153636-B2 | Pyridyl derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-04-10 | — | — | US | disclosed |
| EP-2316825-A1 | Pyridyl derivatives and their use as therapeutic agents | Xenon Pharmaceuticals Inc. (CA) | 2011-05-04 | — | — | EP | disclosed |
| US-20100048584-A1 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-02-25 | — | — | US | disclosed |
| US-7605161-B2 | 1-Pentyl-3-{6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]-pyridin-3-yl}urea; inhibitors of stearoyl-CoA desaturase; cardiovascular disease, diabetes, obesity, metabolic syndrome | XENON PHARMACEUTICALS INC. (CA) | 2009-10-20 | — | — | US | disclosed |
| WO-2008029266-A1 | STEAROYL COA DESATURASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (US) | 2008-03-13 | — | — | WO | disclosed |
| US-20060199802-A1 | Pyridyl derivatives and their use as therapeutic agents | DISCOVERY PARTNERS INTERNATIONAL, INC. | 2006-09-07 | — | — | US | disclosed |
| EP-1651606-A2 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005011656-A2 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048584-A1 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | PRMT9, SNRPD3, SCD | SCD 3/4885KMT2A 3242/4885MEN1 3732/4885 |
| US-20060199802-A1 | Pyridyl derivatives and their use as therapeutic agents | PYCR1, PNPO, UQCRC1 | SCD 6/4885KMT2A 4113/4885MEN1 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.